<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712801</url>
  </required_header>
  <id_info>
    <org_study_id>2015ZX10001001</org_study_id>
    <nct_id>NCT02712801</nct_id>
  </id_info>
  <brief_title>Antiretroviral Regime for Viral Eradication in Newborns</brief_title>
  <official_title>Antiretroviral Regime for Viral Eradication in Newborns After Intervention Failure of Mother-to-child Transmission of HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Women and Children's Health, China CDC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Yunan Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Sichuan Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Guangxi Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Women and Children's Health, China CDC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, controlled, open clinical trial. The trial will be
      carried out in five provinces in China. Pregnant women with HIV infection and at high risk of
      mother-to-child transmission of HIV will be identified. Their newborn babies who are at high
      risk HIV infection will be recruited and randomized into intervention and control groups.
      Children in intervention groups will receive ART and intensive HIV testing after birth.
      Children in control group will receive routine prevention of mother-to-child transmission
      services. All the included children will be followed up and their development and infection
      status will be recorded and compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV infection in children</measure>
    <time_frame>0-18 months old</time_frame>
    <description>Number of children diagnosed with HIV infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional HIV cure in children</measure>
    <time_frame>0-36 months old</time_frame>
    <description>Number of children with functional HIV cure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>0-36 months old</time_frame>
    <description>Number of children died</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART regime for HIV exposed children at high risk of infection</measure>
    <time_frame>0-36 months old</time_frame>
    <description>ART regime to be used for functional HIV cure in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testing algorithm for early infant diagnosis of HIV</measure>
    <time_frame>0-4 weeks old</time_frame>
    <description>Testing methods and algorithm for HIV exposed infants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV/AIDS and Infections</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Dose will be adjusted according to the child's weight.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>AZT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Dose will be adjusted according to the child's weight.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Dose will be adjusted according to the child's weight.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Dose will be adjusted according to the child's weight.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>LPV/r</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children whose mother with HIV infection

          -  children whose mother received antiretroviral drugs after 36 gestational weeks or
             received no drugs before delivery

          -  live birth

        Exclusion Criteria:

          -  birth weight is less than 2000g

          -  Apgar score is less than 3 at 1 minute after birth or less than 6 at 5 minute after
             birth .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Jin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Women and Children's Health, China CDC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ailing Wang, M.D.</last_name>
    <phone>0086-10-62170944</phone>
    <email>ailing@chinawch.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lixia Dou, Ph.D.</last_name>
    <phone>0086-10-62170948</phone>
    <email>doulx@chinawch.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Guangdong Province</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiying Wen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxia Qiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Sichuan Province</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Yunan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Center for Women and Children's Health, China CDC</investigator_affiliation>
    <investigator_full_name>Xi JIN</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>child</keyword>
  <keyword>testing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

